Sudan Loganathan
Stock Analyst at Stephens & Co.
(0.08)
# 1,845
Out of 4,666 analysts
22
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sudan Loganathan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ATNM Actinium Pharmaceuticals | Reiterates: Overweight | $5 | $1.39 | +259.71% | 2 | Nov 19, 2024 | |
| CPRX Catalyst Pharmaceuticals | Initiates: Overweight | $35 | $21.15 | +65.48% | 1 | Nov 18, 2024 | |
| IDYA IDEAYA Biosciences | Initiates: Overweight | $51 | $25.54 | +99.69% | 1 | Nov 18, 2024 | |
| CCCC C4 Therapeutics | Initiates: Equal-Weight | $4 | $4.05 | -1.23% | 1 | Nov 18, 2024 | |
| KYMR Kymera Therapeutics | Initiates: Overweight | $65 | $44.05 | +47.56% | 1 | Nov 18, 2024 | |
| ARVN Arvinas | Initiates: Overweight | $55 | $22.69 | +142.40% | 1 | Nov 18, 2024 | |
| BCYC Bicycle Therapeutics | Initiates: Equal-Weight | $25 | $20.36 | +22.79% | 1 | Nov 8, 2024 | |
| ADCT ADC Therapeutics | Initiates: Overweight | $6 | $1.98 | +203.03% | 1 | Nov 8, 2024 | |
| IMNM Immunome | Initiates: Overweight | $30 | $9.33 | +221.54% | 1 | Nov 8, 2024 | |
| PYXS Pyxis Oncology | Initiates: Overweight | $13 | $3.82 | +240.31% | 1 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $23 → $29 | $34.65 | -16.31% | 2 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $31 | $22.64 | +36.93% | 2 | Oct 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $9.63 | +159.61% | 2 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $0.50 | +904.02% | 2 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $8 | $0.58 | +1,276.70% | 1 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $3.97 | +403.78% | 1 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $140 | $94.81 | +47.66% | 1 | May 14, 2024 |
Actinium Pharmaceuticals
Nov 19, 2024
Reiterates: Overweight
Price Target: $5
Current: $1.39
Upside: +259.71%
Catalyst Pharmaceuticals
Nov 18, 2024
Initiates: Overweight
Price Target: $35
Current: $21.15
Upside: +65.48%
IDEAYA Biosciences
Nov 18, 2024
Initiates: Overweight
Price Target: $51
Current: $25.54
Upside: +99.69%
C4 Therapeutics
Nov 18, 2024
Initiates: Equal-Weight
Price Target: $4
Current: $4.05
Upside: -1.23%
Kymera Therapeutics
Nov 18, 2024
Initiates: Overweight
Price Target: $65
Current: $44.05
Upside: +47.56%
Arvinas
Nov 18, 2024
Initiates: Overweight
Price Target: $55
Current: $22.69
Upside: +142.40%
Bicycle Therapeutics
Nov 8, 2024
Initiates: Equal-Weight
Price Target: $25
Current: $20.36
Upside: +22.79%
ADC Therapeutics
Nov 8, 2024
Initiates: Overweight
Price Target: $6
Current: $1.98
Upside: +203.03%
Immunome
Nov 8, 2024
Initiates: Overweight
Price Target: $30
Current: $9.33
Upside: +221.54%
Pyxis Oncology
Nov 8, 2024
Initiates: Overweight
Price Target: $13
Current: $3.82
Upside: +240.31%
Oct 30, 2024
Maintains: Equal-Weight
Price Target: $23 → $29
Current: $34.65
Upside: -16.31%
Oct 14, 2024
Reiterates: Overweight
Price Target: $31
Current: $22.64
Upside: +36.93%
Aug 6, 2024
Reiterates: Overweight
Price Target: $25
Current: $9.63
Upside: +159.61%
May 24, 2024
Reiterates: Overweight
Price Target: $5
Current: $0.50
Upside: +904.02%
May 14, 2024
Initiates: Overweight
Price Target: $8
Current: $0.58
Upside: +1,276.70%
May 14, 2024
Initiates: Overweight
Price Target: $20
Current: $3.97
Upside: +403.78%
May 14, 2024
Initiates: Overweight
Price Target: $140
Current: $94.81
Upside: +47.66%